In clinical practice, the formulation of preoperative treatment plans for gliomas, such as whether to perform total surgical resection or whether preoperative targeted therapy is needed, depends heavily on tumor grading and isocitrate dehydrogenase (IDH) status (Olar et al., 2015; van den Bent et al., 2024). This evidence concerns the gene IDH3A and neoplasm.